Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Chien, H., Morreall, D., Patil, V., Rasmussen, K. M., Li, C., Yong, C. M., Burningham, Z., Masaquel, A., Halloran, M., De Long-Sieg, E., Schulz, M., Sauer, B. C., & Halwani, A. S. Future oncology (London, England), 17(4):411–422, February, 2021. Place: Englanddoi abstract bibtex Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse large B-cell lymphoma patients completing second-line treatment (2L) in 2000-2016. Treatments were classified as aggressive/nonaggressive. Analyses included descriptive statistics and the Kaplan-Meier estimation of progression-free survival and overall survival. Results: Two hundred and seventy patients received 2L. During median 9.7-month follow-up starting from 2L, 470 regimens were observed, averaging 2.7 regimens/patient: 219 aggressive, 251 nonaggressive. One hundred and twenty-one patients proceeded to third-line, 50 to fourth-line and 18 to fifth-line treatment. Median progression-free survival in 2L was 5.2 months. Median overall survival was 9.5 months. Forty-four patients (16.3%) proceeded to bone marrow transplant. Conclusion: More effective, less toxic treatments are needed and should be initiated earlier in treatment trajectory.
@article{chien_real-world_2021-1,
title = {Real-world practice patterns and outcomes in {Veterans} with relapsed/refractory diffuse large {B}-cell lymphoma.},
volume = {17},
issn = {1744-8301 1479-6694},
doi = {10.2217/fon-2020-0522},
abstract = {Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients \& methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse large B-cell lymphoma patients completing second-line treatment (2L) in 2000-2016. Treatments were classified as aggressive/nonaggressive. Analyses included descriptive statistics and the Kaplan-Meier estimation of progression-free survival and overall survival. Results: Two hundred and seventy patients received 2L. During median 9.7-month follow-up starting from 2L, 470 regimens were observed, averaging 2.7 regimens/patient: 219 aggressive, 251 nonaggressive. One hundred and twenty-one patients proceeded to third-line, 50 to fourth-line and 18 to fifth-line treatment. Median progression-free survival in 2L was 5.2 months. Median overall survival was 9.5 months. Forty-four patients (16.3\%) proceeded to bone marrow transplant. Conclusion: More effective, less toxic treatments are needed and should be initiated earlier in treatment trajectory.},
language = {eng},
number = {4},
journal = {Future oncology (London, England)},
author = {Chien, Hsu-Chih and Morreall, Deborah and Patil, Vikas and Rasmussen, Kelli M. and Li, Chunyang and Yong, Christina M. and Burningham, Zachary and Masaquel, Anthony and Halloran, Mary and De Long-Sieg, Elisha and Schulz, Mathias and Sauer, Brian C. and Halwani, Ahmad S.},
month = feb,
year = {2021},
pmid = {33115291},
note = {Place: England},
keywords = {Aged, Humans, Male, Middle Aged, outcomes, Female, real-world evidence, Adult, Aged, 80 and over, Bone Marrow Transplantation, Lymphoma, Large B-Cell, Diffuse/mortality/*therapy, practice patterns, Recurrence, relapsed/refractory diffuse large B-cell lymphoma, Veterans},
pages = {411--422},
}
Downloads: 0
{"_id":"dgSzG7nexCDb5L2ug","bibbaseid":"chien-morreall-patil-rasmussen-li-yong-burningham-masaquel-etal-realworldpracticepatternsandoutcomesinveteranswithrelapsedrefractorydiffuselargebcelllymphoma-2021","author_short":["Chien, H.","Morreall, D.","Patil, V.","Rasmussen, K. M.","Li, C.","Yong, C. M.","Burningham, Z.","Masaquel, A.","Halloran, M.","De Long-Sieg, E.","Schulz, M.","Sauer, B. C.","Halwani, A. S."],"bibdata":{"bibtype":"article","type":"article","title":"Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.","volume":"17","issn":"1744-8301 1479-6694","doi":"10.2217/fon-2020-0522","abstract":"Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse large B-cell lymphoma patients completing second-line treatment (2L) in 2000-2016. Treatments were classified as aggressive/nonaggressive. Analyses included descriptive statistics and the Kaplan-Meier estimation of progression-free survival and overall survival. Results: Two hundred and seventy patients received 2L. During median 9.7-month follow-up starting from 2L, 470 regimens were observed, averaging 2.7 regimens/patient: 219 aggressive, 251 nonaggressive. One hundred and twenty-one patients proceeded to third-line, 50 to fourth-line and 18 to fifth-line treatment. Median progression-free survival in 2L was 5.2 months. Median overall survival was 9.5 months. Forty-four patients (16.3%) proceeded to bone marrow transplant. Conclusion: More effective, less toxic treatments are needed and should be initiated earlier in treatment trajectory.","language":"eng","number":"4","journal":"Future oncology (London, England)","author":[{"propositions":[],"lastnames":["Chien"],"firstnames":["Hsu-Chih"],"suffixes":[]},{"propositions":[],"lastnames":["Morreall"],"firstnames":["Deborah"],"suffixes":[]},{"propositions":[],"lastnames":["Patil"],"firstnames":["Vikas"],"suffixes":[]},{"propositions":[],"lastnames":["Rasmussen"],"firstnames":["Kelli","M."],"suffixes":[]},{"propositions":[],"lastnames":["Li"],"firstnames":["Chunyang"],"suffixes":[]},{"propositions":[],"lastnames":["Yong"],"firstnames":["Christina","M."],"suffixes":[]},{"propositions":[],"lastnames":["Burningham"],"firstnames":["Zachary"],"suffixes":[]},{"propositions":[],"lastnames":["Masaquel"],"firstnames":["Anthony"],"suffixes":[]},{"propositions":[],"lastnames":["Halloran"],"firstnames":["Mary"],"suffixes":[]},{"propositions":[],"lastnames":["De","Long-Sieg"],"firstnames":["Elisha"],"suffixes":[]},{"propositions":[],"lastnames":["Schulz"],"firstnames":["Mathias"],"suffixes":[]},{"propositions":[],"lastnames":["Sauer"],"firstnames":["Brian","C."],"suffixes":[]},{"propositions":[],"lastnames":["Halwani"],"firstnames":["Ahmad","S."],"suffixes":[]}],"month":"February","year":"2021","pmid":"33115291","note":"Place: England","keywords":"Aged, Humans, Male, Middle Aged, outcomes, Female, real-world evidence, Adult, Aged, 80 and over, Bone Marrow Transplantation, Lymphoma, Large B-Cell, Diffuse/mortality/*therapy, practice patterns, Recurrence, relapsed/refractory diffuse large B-cell lymphoma, Veterans","pages":"411–422","bibtex":"@article{chien_real-world_2021-1,\n\ttitle = {Real-world practice patterns and outcomes in {Veterans} with relapsed/refractory diffuse large {B}-cell lymphoma.},\n\tvolume = {17},\n\tissn = {1744-8301 1479-6694},\n\tdoi = {10.2217/fon-2020-0522},\n\tabstract = {Aim: To describe practices and outcomes in veterans with relapsed/refractory diffuse large B-cell lymphoma. Patients \\& methods: Using Veteran Affairs Cancer Registry System and electronic health record data, we identified relapsed/refractory diffuse large B-cell lymphoma patients completing second-line treatment (2L) in 2000-2016. Treatments were classified as aggressive/nonaggressive. Analyses included descriptive statistics and the Kaplan-Meier estimation of progression-free survival and overall survival. Results: Two hundred and seventy patients received 2L. During median 9.7-month follow-up starting from 2L, 470 regimens were observed, averaging 2.7 regimens/patient: 219 aggressive, 251 nonaggressive. One hundred and twenty-one patients proceeded to third-line, 50 to fourth-line and 18 to fifth-line treatment. Median progression-free survival in 2L was 5.2 months. Median overall survival was 9.5 months. Forty-four patients (16.3\\%) proceeded to bone marrow transplant. Conclusion: More effective, less toxic treatments are needed and should be initiated earlier in treatment trajectory.},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {Future oncology (London, England)},\n\tauthor = {Chien, Hsu-Chih and Morreall, Deborah and Patil, Vikas and Rasmussen, Kelli M. and Li, Chunyang and Yong, Christina M. and Burningham, Zachary and Masaquel, Anthony and Halloran, Mary and De Long-Sieg, Elisha and Schulz, Mathias and Sauer, Brian C. and Halwani, Ahmad S.},\n\tmonth = feb,\n\tyear = {2021},\n\tpmid = {33115291},\n\tnote = {Place: England},\n\tkeywords = {Aged, Humans, Male, Middle Aged, outcomes, Female, real-world evidence, Adult, Aged, 80 and over, Bone Marrow Transplantation, Lymphoma, Large B-Cell, Diffuse/mortality/*therapy, practice patterns, Recurrence, relapsed/refractory diffuse large B-cell lymphoma, Veterans},\n\tpages = {411--422},\n}\n\n","author_short":["Chien, H.","Morreall, D.","Patil, V.","Rasmussen, K. M.","Li, C.","Yong, C. M.","Burningham, Z.","Masaquel, A.","Halloran, M.","De Long-Sieg, E.","Schulz, M.","Sauer, B. C.","Halwani, A. S."],"key":"chien_real-world_2021-1","id":"chien_real-world_2021-1","bibbaseid":"chien-morreall-patil-rasmussen-li-yong-burningham-masaquel-etal-realworldpracticepatternsandoutcomesinveteranswithrelapsedrefractorydiffuselargebcelllymphoma-2021","role":"author","urls":{},"keyword":["Aged","Humans","Male","Middle Aged","outcomes","Female","real-world evidence","Adult","Aged","80 and over","Bone Marrow Transplantation","Lymphoma","Large B-Cell","Diffuse/mortality/*therapy","practice patterns","Recurrence","relapsed/refractory diffuse large B-cell lymphoma","Veterans"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/RyxHRMzXC8JQ3ifpb","dataSources":["YrmuDu8kXyyMRQSAd","Paz5SQAsutNo54mvh"],"keywords":["aged","humans","male","middle aged","outcomes","female","real-world evidence","adult","aged","80 and over","bone marrow transplantation","lymphoma","large b-cell","diffuse/mortality/*therapy","practice patterns","recurrence","relapsed/refractory diffuse large b-cell lymphoma","veterans"],"search_terms":["real","world","practice","patterns","outcomes","veterans","relapsed","refractory","diffuse","large","cell","lymphoma","chien","morreall","patil","rasmussen","li","yong","burningham","masaquel","halloran","de long-sieg","schulz","sauer","halwani"],"title":"Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.","year":2021}